Mereo BioPharma Group plc 8-K

What Happened
Mereo BioPharma Group plc announced its financial results for the year ended December 31, 2025 and provided recent corporate highlights. The announcement was made via a press release dated March 19, 2026, which the company furnished as Exhibit 99.1 to its Current Report on Form 8‑K (filed March 19, 2026) under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: March 19, 2026 (Form 8‑K).
• Reporting period: year ended December 31, 2025.
• Press release containing the results and highlights is furnished as Exhibit 99.1 to the 8‑K.
• Report signed on behalf of the company by Christine Fox, Chief Financial Officer.

Why It Matters
This 8‑K notifies investors that Mereo has publicly released its full‑year 2025 results and related corporate updates; the 8‑K itself furnishes the press release rather than embedding detailed financial tables in the filing. Retail investors should review the Exhibit 99.1 press release (or the company’s investor relations materials) to see the specific earnings, revenue, cash position, and any guidance or strategic updates disclosed.